

Martee Hensley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12075531/publications.pdf>

Version: 2024-02-01

11
papers

2,443
citations

840776

11
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

1992
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk-Reducing Salpingo-oophorectomy in Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>New England Journal of Medicine</i> , 2002, 346, 1609-1615.	27.0	1,363
2	Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in <i>BRCA</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2002, 20, 1260-1268.	1.6	395
3	Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. <i>Cancer</i> , 2004, 101, 1455-1462.	4.1	152
4	Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. <i>Gynecologic Oncology</i> , 2003, 89, 281-287.	1.4	130
5	A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 594-604.	2.5	99
6	Surgical Resection of Pulmonary and Extrapulmonary Recurrences of Uterine Leiomyosarcoma. <i>Gynecologic Oncology</i> , 2002, 87, 287-294.	1.4	84
7	Histopathologic Prognostic Factors in Stage I Leiomyosarcoma of the Uterus. <i>American Journal of Surgical Pathology</i> , 2011, 35, 522-529.	3.7	75
8	“Low-Grade Leiomyosarcoma” and Late-Recurring Smooth Muscle Tumors of the Uterus. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1626-1637.	3.7	54
9	A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. <i>Cancer</i> , 2007, 110, 2458-2466.	4.1	43
10	Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials. <i>Gynecologic Oncology</i> , 2007, 106, 469-475.	1.4	34
11	Consolidation strategies in ovarian cancer: Observations for future clinical trials. <i>Gynecologic Oncology</i> , 2010, 116, 66-71.	1.4	14